Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Editorial
. 2018 Sep;7(Suppl 3):S208-S210.
doi: 10.21037/tlcr.2018.07.15.

Combination chemotherapy and immunotherapy in metastatic non-small cell lung cancer: a setback for personalized medicine?

Monica S Chatwal  1 , Tawee Tanvetyanon  2
Affiliations
Editorial

Combination chemotherapy and immunotherapy in metastatic non-small cell lung cancer: a setback for personalized medicine?

Monica S Chatwal et al. Transl Lung Cancer Res. 2018 Sep.
No abstract available

PubMed Disclaimer

Conflict of interest statement

Conflicts of Interest: The authors have no conflicts of interest to declare.

Comment on

  • Pembrolizumab plus Chemotherapy in Metastatic Non-Small-Cell Lung Cancer.
    Gandhi L, Rodríguez-Abreu D, Gadgeel S, Esteban E, Felip E, De Angelis F, Domine M, Clingan P, Hochmair MJ, Powell SF, Cheng SY, Bischoff HG, Peled N, Grossi F, Jennens RR, Reck M, Hui R, Garon EB, Boyer M, Rubio-Viqueira B, Novello S, Kurata T, Gray JE, Vida J, Wei Z, Yang J, Raftopoulos H, Pietanza MC, Garassino MC; KEYNOTE-189 Investigators. Gandhi L, et al. N Engl J Med. 2018 May 31;378(22):2078-2092. doi: 10.1056/NEJMoa1801005. Epub 2018 Apr 16. N Engl J Med. 2018. PMID: 29658856 Clinical Trial.

References

    1. Nivolumab (Opdivo) label information. NIH U.S. National Library of Medicine. Available online: https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=f570b9c4-6846-4.... Accessed July 2, 2018.
    1. Borghaei H, Paz-Ares L, Horn L, et al. Nivolumab versus Docetaxel in Advanced Nonsquamous Non-Small-Cell Lung Cancer. N Engl J Med 2015;373:1627-39. 10.1056/NEJMoa1507643 - DOI - PMC - PubMed
    1. More Immunotherapy Options Approved for Lung Cancer. NIH National Cancer Institute. 2016. Available online: https://www.cancer.gov/news-events/cancer-currents-blog/2016/fda-atezoli.... Accessed July 2, 2018.
    1. Reck M, Rodríguez-Abreu D, Robinson AG, et al. Pembrolizumab versus Chemotherapy for PD-L1–Positive Non–Small-Cell Lung Cancer. N Engl J Med 2016;375:1823-33. 10.1056/NEJMoa1606774 - DOI - PubMed
    1. Gandhi L, Rodriguez-Abreu D, Gadgeel S, et al. Pembrolizumab plus Chemotherapy in Metastatic Non-Small-Cell Lung Cancer. N Engl J Med 2018;378:2078-92. 10.1056/NEJMoa1801005 - DOI - PubMed